Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, August 2025
Year of Publication2025
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
We recommend against treatment with casirivimab-imdevimab for all patients with COVID-19
Recommended against
Strong
Notes and Remarks
- The GDG considered in vitro data demonstrating that casirivimab-imdevimab does not neutralize the currently circulating variants of SARS-CoV-2 and their subvariants.
- There was consensus among the panel that the meaningful reduction of in vitro neutralization activity strongly suggests absence of clinical effectiveness of monoclonal antibodies such as sotrovimab and casirivimab-imdevimab.
- There was also consensus regarding the need for clinical trial evidence in order to confirm clinical effectiveness of new monoclonal antibodies that reliably neutralize circulating strains in vitro. Practical info Given the strong recommendation against using casirivimab-imdevimab for all patients with COVID-19, practical considerations were felt to be less relevant here.
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Therapeutics and COVID-19: living guideline, 13 January 2023.
Year2023
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, 10 November 2023.
Year2023
InstitutionWorld Health Organization